OptiMARK™ 0.5 mmol mL (Gadoversetamide Injection) PRESCRIBING INFORMATION Rx only Mallinckrodt Inc. May 2013 - Injection fibrosis - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2013-05-23 16:04:28 Medicine MRI contrast agent Nephrogenic systemic fibrosis Gadolinium Magnetic resonance imaging Renal failure Gadoversetamide Chemistry Nephrology Matter		OptiMARK™ 0.5 mmol/mL (Gadoversetamide Injection) PRESCRIBING INFORMATION Rx only Mallinckrodt Inc. May 2013 Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 293,89 KB Share Document on Facebook

	THE JOURNAL OF CHEMICAL PHYSICS 126, 181102 共2007兲 Ab initio simulation of a gadolinium-based magnetic resonance imaging contrast agent in aqueous solution Rodolphe Polleta兲 Laboratoire Francis Perrin, DSM/DRECAM/ DocID: 1s1IP - View Document
	Synthetic Phase Sensitive Inversion Recovery Late Gadolinium Enhancement from Post-contrast T1-mapping Shows Excellent Agreement with Conventional PSIR-LGE for Diagnosing Myocardial Scar Abdula G, Sörensson P, Nickander DocID: 1pN1h - View Document
	Theranostics 2016, Vol. 6, Issue 10 Ivyspring International Publisher Research Paper DocID: 1oOeM - View Document
	Current Version: 2.0 Revision Date: Sep 5, 2012 Material Safety Data Sheet Identity: Gadolinium DocID: 1oCb0 - View Document
	Paper Formatting Instructions - Mo DocID: 1nPdU - View Document